Sutro Biopharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net (Loss) Income Per Share Attributable to Common Stockholders (Tables)

Net (Loss) Income Per Share Attributable to Common Stockholders (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Computation of Company's Basic and Diluted Net (Loss) Income Per Share

The following table sets forth the computation of the Company’s basic and diluted net (loss) income per share attributable to common stockholders.

	Year Ended December 31,
	2018			2017			2016
	(in thousands, except share and per share amounts)
Numerator:
Net (loss) income	$	(35,317	)	$	(19,688	)	$	1,702
Noncumulative dividends on redeemable convertible preferred stock		-			-			(1,702	)
Net loss attributable to common stockholders, basic and diluted	$	(35,317	)	$	(19,688	)	$	-
Denominator:
Shares used in computing net loss per share attributable to common stockholders, basic and diluted		5,758,875			447,946			407,735
Net loss per share, attributable to common stockholders, basic and diluted	$	(6.13	)	$	(43.95	)	$	-

Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share

The following common stock equivalents were excluded from the computation of diluted net income (loss) per share for the year ended December 31, 2016 as net income attributable to common stock holders was nil, and for the years ended December 31, 2018 and 2017 because including them would have been antidilutive:

	Year Ended December 31,
	2018		2017		2016
Redeemable convertible preferred stock		-		5,063,404		5,063,404
Common stock options and award issued and outstanding		3,422,958		835,320		796,907
Warrants to purchase redeemable convertible preferred stock		-		93,527		74,767
Warrants to purchase common stock		71,813		1,099		1,099
Early exercised shares of common stock		-		2,374		17,140
Shares to be issued under ESPP		29,416		-		-
Total		3,524,187		5,995,724		5,953,317